Investing

Immuneering : IMRX

IMRX

Stock Data

$5.37

$0.13 (2.48%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Immuneering Corp Class A is a pioneering force in the fight against cancer, focusing on creating medicines for a wide range of cancer patients. With its flagship products, IMM-1-104 and IMM-6-415, the company targets various cancers including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those caused by RAS and/or RAF mutations. Founded in 2008 and headquartered in Cambridge, Massachusetts, Immuneering is at the forefront of clinical-stage oncology research, aiming to bring innovative treatments from the lab to the patient.

All Immuneering Articles

2 Articles

Joel South | Mar 9, 2026 at 11:15 AM EDT

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional…

Gerelyn Terzo | Jul 9, 2024 at 10:47 AM EDT

3 Penny Stocks With 735% Average Upside, According to Wall Street

With the third quarter in full swing, the bulls have not lost their grip on equities. The market momentum isn’t…